TrialThe New England journal of medicine2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Scott J Antonia et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1,494 papers cite itlatest 60 shown
this paperpooled ittrialcites it